First human tests begin for potential new autoimmune disease treatment
NCT ID NCT07363590
Summary
This is an early-stage study testing a new medication called MK-1045 in people with lupus and rheumatoid arthritis. The main goal is to check the safety and side effects of different doses and see how the body processes the drug. Researchers will also measure if the treatment reduces certain immune cells (B cells) in the blood.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Anima Diepenbeek ( Site 0601)
RECRUITINGDiepenbeek, Limburg, 3590, Belgium
Contact Phone: •••-•••-••••
-
Arensia Exploartory Medicine ( Site 1301)
RECRUITINGTbilisi, 0112, Georgia
Contact Phone: •••-•••-••••
-
Istituto Clinico Humanitas- IRCCS ( Site 1902)
RECRUITINGRozzano, Milano, 20089, Italy
Contact Phone: •••-•••-••••
-
PMSI Republican Clinical Hospital "T.Mosneaga" ( Site 1001)
RECRUITINGChisinau, 2025, Moldova
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.